Varex Imaging Corporation
Rank #261DeclineVREX · Nasdaq · Healthcare
Varex Imaging Corporation (VREX) — Rank #261 by gross profitability (GP/assets 0.26) · ROE -14.2% · Piotroski F-Score 6 / 9.
As-of 2026-09-15 · CIK 0001681622 · all metrics point-in-time as of the filing date.
About
Varex Imaging Corporation designs, manufactures, and sells X-ray imaging components.
Show moreShow less
It operates through two segments, Medical and Industrial. The Medical segment designs, manufactures, sells, and services X-ray imaging components, comprising X-ray tubes, digital detectors and accessories, ionization chambers, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and heat exchangers. This segment's products are used in a range of applications, including CT, mammography, oncology, cardiac, surgery, dental, and other diagnostic radiography uses. The Industrial segment designs, develops, manufactures, sells, and services Linatron X-ray linear accelerators, non-intrusive cargo inspection systems, X-ray tubes, digital detectors, high voltage connectors, and coolers for use in security and inspection applications, such as baggage screening at airports, cargo screening at ports and borders, and nondestructive testing, irradiation, and inspection in various applications. It sells its products through imaging system original equipment manufacturers, independent service companies, and distributors, as well as directly to end-users. The company has operations in North America, Latin America, Europe, the Middle East, India, Africa, Asia, and Australia.
The company was incorporated in 2016 and is headquartered in Salt Lake City, Utah.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- DE
- Filer Category
- Accelerated filer
- Fiscal Year End
- October 2
- Website
- vareximaging.com
Financials
Strengthening
Direction over 5 fiscal years
- Free cash flowimproving
- Gross marginstable
- Gross profitabilityimproving
- Net cashimproving
- Operating marginimproving
- Return on equityimproving
- Share count (dilution)improving
Monitoring diagnostic of business direction — not a prediction of returns.
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2024-09-27filed 2024-11-19 | 2023-09-29filed 2023-11-16 | 2022-09-30filed 2022-11-18 | 2021-10-01filed 2021-11-19 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 811.0 | 893.4 | 859.4 | 818.1 |
| Revenue growth (YoY) | -9.2% | 4.0% | 5.0% | 10.8% |
| Gross profit | 256.9 | 290.3 | 283.5 | 271.5 |
| Gross margin | 31.7% | 32.5% | 33.0% | 33.2% |
| Net income | (47.7) | 48.2 | 30.3 | 17.4 |
| Net margin | -5.9% | 5.4% | 3.5% | 2.1% |
| EPS (diluted) | -$1.17 | $1.08 | $0.73 | $0.43 |
| EPS growth (YoY) | -208.3% | 47.9% | 69.8% | — |
| Cash flow | ||||
| Operating cash flow | 47.3 | 108.4 | 16.9 | 92.6 |
| Capital expenditures | 26.9 | — | 5.4 | 15.1 |
| Free cash flow | 20.4 | — | 11.5 | 77.5 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?